JPRN-UMIN000011806已完成2 期
Randomized phase II study of Gemcitabine and S-1 combination therapy versus S-1 in patients with Gemcitabine-refractory unresectable advanced Pancreatic Cancer - Randomized phase II study of GS vs. S-1 in patients with Gem-refractory unresectable advanced Pancreatic Cancer
Osaka Pancreas Forum0 个研究点目标入组 49 人开始时间: 2013年9月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients who have previously administered 5-FU including S-1 2)Severe complications 3)Simultaneous or metachronous (within 5 years) double cancers, with the exception of intramucosal tumor curable with local therapy 4)Severe Gem hypersensitivity 5)Patients who have not undergone radiotherapy 6)Active infections 7)Patients with HBs antigen-positive or with HCV antibody-positive 8)Patients who have previous history of radiotherapy to the chest 9)Uncontrollable watery diarrhea 10)Presence of metastasis in central nervous system 11)Severe mental disorders 12)Pregnant or lactating women, or women with known or suspected pregnancy and men who want let to pregnancy 13)Required to continue to take flucytosine, phenytoin, and warfarin 14)Patients seems inadequate for this study by investigators
研究者
相似试验
已完成
2 期
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaJPRN-UMIN000021484Clinical study group of Osaka university, Hepato-Biliary- Pancreatic group100
已完成
2 期
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine in advanced biliary tract cancer (GS-COMBI).Advanced biliary tract cancerJPRN-UMIN000001703Japanese Endoscopist & IVRists group for Biliary Tract Cancer (JEIBIC)62
招募中
2 期
PDAC-GS/GA-rP2JPRN-jRCTs051180122Kobayashi Syogo100
招募中
2 期
Randomized phase II study of gemcitabine and S-1 combination therapy versus S-1 in patients with gemcitabine-refractory advanced pancreatic canceradvanced pancreatic cancerJPRN-UMIN000007173Tokai University Hospital Kanagawa Cancer Center90
已完成
2 期
Phase II study of gemcitabine and S-1 combination therapy in advanced pancreatic cancer with malignant ascites.pancreatic cancer with ascitesJPRN-UMIN000003269ational Cancer Center Hospital East Hepatobiliary and Pancreatic Oncology Division36